Reported about 19 hours ago
InflaRx has discontinued its Phase 3 trial for vilobelimab in treating pyoderma gangrenosum due to a recommendation from the Independent Data Monitoring Committee after a futility analysis. The company will now redirect its efforts towards INF904, an orally administered small molecule inhibitor, with Phase 2a data expected in summer 2025 for chronic spontaneous urticaria and hidradenitis suppurativa. Despite the trial halt, vilobelimab remains available under Emergency Use Authorization for COVID-19 treatment in the US.
Source: YAHOO